Document Detail

Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis.
MedLine Citation:
PMID:  21557144     Owner:  NLM     Status:  In-Data-Review    
The chemotherapeutic agent mitoxantrone is approved for the treatment of aggressive multiple sclerosis (MS) in adults. Its use, however, is limited by the risk of severe adverse events including cardiotoxicity, myelosuppression, liver toxicity and secondary leukemia. The aim of this retrospective study is to present data on the safety, tolerability and efficacy of mitoxantrone in a small cohort of children with MS. 4 pediatric MS patients with a high relapse rate or severe, disabling relapses were treated with mitoxantrone and followed for 3.8-18 years. The cumulative dose of mitoxantrone was 36, 68, 84 and 120 mg/m (2), respectively. The frequency and severity of relapses as well as disability scores, decreased in the year after treatment onset. Short-term adverse events were transient in all cases. Cardiac monitoring by transthoracic echocardiography (TTE) showed asymptomatic left ventricular dysfunction during treatment in 1 patient, which was again normal at the next assessment. Long-term adverse events, including late-onset mitoxantrone-induced cardiotoxicity or secondary leukemia did not occur during the follow-up period. In our cohort of pediatric MS patients, mitoxantrone showed short-term reduction of disease activity and no long-term adverse events on follow-up. However, the risk of mitoxantrone-induced cardiotoxicity or toxic leukemia remains a life-long threat.
B Kornek; G Bernert; K Rostasy; E Mlczoch; M Feucht; D Prayer; K Vass; R Seidl
Related Documents :
8880764 - Hydrocephalus and epilepsy: an actuarial analysis.
11150444 - Portal venous decompression with h-type mesocaval shunt using autologous vein graft: a ...
15063264 - Bidirectional glenn procedure without cardiopulmonary bypass.
8508334 - Use of acetylsalicylic acid to improve patency of subclavian to pulmonary artery gore-t...
23804554 - Progression in disability and regional grey matter atrophy in relapsing-remitting multi...
22490724 - Endovenous laser ablation for major varicose tributaries.
Publication Detail:
Type:  Journal Article     Date:  2011-05-09
Journal Detail:
Title:  Neuropediatrics     Volume:  42     ISSN:  1439-1899     ISO Abbreviation:  Neuropediatrics     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-05-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8101187     Medline TA:  Neuropediatrics     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  7-12     Citation Subset:  IM    
Copyright Information:
© Georg Thieme Verlag KG Stuttgart · New York.
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of the prognostic value of horner syndrome in perinatal brachial plexus palsy.
Next Document:  Cutaneous, mediastinal and hepatic hemangiomas in a girl followed during 12 years.